Skip to main content
. 2020 Aug 14;11:1123. doi: 10.3389/fphar.2020.01123

Table 3.

Top 20 International blockbuster cancer drugs in 2018, [USD].

Lp. Brand Name Active Substance Manufacturer Condition or Diseases Treated Global Sales (USD)
1 Avastin Bevacizumab Roche Breast, colorectal, lung, kidney, ovarian cancers 6.7 bln
2 Revlimid Lenalidomide Celgene Multiple myeloma 4.2 bln
3 Rituxan Rituximab Roche Non-Hodgkins Lymphoma, chronic lymphocytic leukemia 7.5 bln
4 Herceptin Trastuzumab Roche HER2+ breast cancer 6.5 bln
5 Imbruvica Ibrutinib capsules Johnson & Johnson/Pharmacyclics Mantel cell lymphoma, chronic lymphocetic leukemia 5.3 bln
6 Gleevec Imatinib Novartis Chronic myeloid leukemia, gastrointestinal stromal tumors 4.7 bln
7 Alimta Pemetrexed Eli Lilly Nonsmall cell lung cancer 2.5 bln
8 Velcade Bortezomib Johnson & Johnson/Takeda Multiple myeloma, mantle cell lymphoma 2.6 bln
9 Erbitux Cetuximab BMS/Merck Serono Colorectal, head, and neck cancers 1.9 bln
10 Gardasil Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant Merck & Co. Cervical cancer 1.8 bln
11 Zytiga Abiraterone acetate Johnson & Johnson Prostate cancer 1.7 bln
12 Xeloda Capecitabine Roche Breast, colorectal cancers 1.6 bln
13 Tarceva Erlotinib Roche Nonsmall-cell lung, pancreatic cancers 1.4 bln
14 Afinitor Everolimus Novartis Breast cancer 1.3 bln
15 Tasigna Nilotinib Novartis Chronic myeloid leukemia 1.3 bln
16 Sutent Sunitinib Malate Pfizer Renal cell sarcoma, gastrointestinal stromal tumors 1.2 bln
17 Nexavar Sorafenib Bayer Renal cell sarcoma, liver cancer 1.0 bln
18 Xgeva Denosumab Amgen Bone mestases 1.0 bln
19 Zoladex Goserelin acetate AstraZeneca Breast, prostate cancer 1.0 bln
20 Yervoy Ipilimumab BMS Melanoma 960 mln

Source: www.thebalance.com [access: 17.03.2018].